- Report
- August 2024
- 142 Pages
Global
From €2851EUR$2,999USD£2,395GBP
- Report
- March 2025
- 89 Pages
Global
From €5324EUR$5,600USD£4,472GBP
- Report
- July 2024
- 141 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Report
- June 2024
- 145 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Report
- November 2024
- 179 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- October 2024
- 196 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- October 2024
- 190 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- October 2024
- 120 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- December 2024
- 175 Pages
Global
From €4753EUR$5,000USD£3,993GBP
- Report
- October 2023
- 178 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- November 2023
- 182 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- February 2024
- 115 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- June 2023
- 107 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- January 2025
- 132 Pages
Global
From €903EUR$950USD£759GBP

The Breast Cancer Liquid Biopsy Testing Device market is a rapidly growing segment of the Women's Health industry. This technology is used to detect and monitor breast cancer in women, allowing for earlier diagnosis and more effective treatment. Liquid biopsy testing devices use a small sample of blood to detect circulating tumor cells (CTCs) and other biomarkers associated with breast cancer. This technology is non-invasive and can provide more accurate results than traditional biopsy methods. It also has the potential to reduce the cost of diagnosis and treatment.
The Breast Cancer Liquid Biopsy Testing Device market is expected to continue to grow as more women seek out this technology for early detection and monitoring of breast cancer. Companies in this market include Guardant Health, Biocept, and Exosome Diagnostics. Show Less Read more